Navigation Links
Yisheng Biopharma Announces Completion of Phase I Clinical Study of a Novel Hepatitis B Vaccine with PIKA Adjuvant
Date:11/21/2016

BEIJING, Nov. 21, 2016 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological therapeutics, today announced the completion of Phase I clinical trial of PIKA Hepatitis B vaccine, an investigational vaccine designed to provide both prophylactic and therapeutic benefits against hepatitis B virus infection. This vaccine candidate is a proprietary product independently developed by Yisheng Biopharma, using its own toll-like receptor-3 (TLR-3) agonist technology platform ("PIKA"). This technology was named a "National Key Medicine Innovation" in 2013 and funded by the National Ministry of Science and Technology of China. The PIKA adjuvant platform has been demonstrated with good safety profile in multiple clinical trials of Yisheng's rabies vaccine.

Hepatitis B is a potentially life-threatening viral infection that attacks the liver and can cause both acute and chronic disease. An estimated 240 million people globally are chronically infected with the virus. More than 686,000 people die every year due to complications of hepatitis B, including cirrhosis and liver cancer. Hepatitis B can be prevented by effective vaccines.

The Phase I clinical study was conducted at the Singapore General Hospital (SGH) and Changi General Hospital (CGH) in Singapore, and the trial enrolled 32 healthy volunteers. This randomized, double blind, active-controlled, dose escalation study was to evaluate the safety, tolerability and immunogenicity of the investigational PIKA hepatitis B vaccine. PIKA hepatitis B vaccine is a three-dose vaccine with the full course completed within two months, as opposed to three-dose vaccination of the standard licensed products within 6 months.

Dr. Zhongkai Shi, who is overseeing the clinical program in Singapore, commented, "We are pleased with the results of this study in which PIKA hepatitis B vaccine exhibited good safety and tolerability. We are also encouraged by the observation of the robust immunogenicity among the human subjects immunized with the PIKA hepatitis B vaccine."

Dr. Shi continued, "PIKA's potent anti-viral and robust immune-stimulating capability makes PIKA platform well suited for the development of both preventive and therapeutic vaccine against Hepatitis B virus. Such encouraging data is setting up good foundation to initiate a Phase II clinical study with expanded study population and to further evaluate the clinical safety, immunogenicity and efficacy of the investigational vaccine. We are looking forward to updating the progress on these fronts as it moves forward. This phase 1 data further demonstrates the broad potential of our PIKA adjuvant platform and we are committed to developing a broad pipeline of products to address unmet medical needs."

About PIKA Adjuvant Technology and Hepatitis B Vaccine
PIKA adjuvant technology is a proprietary technology developed in-house at Yisheng Biopharma, which is delivering toll-like receptor-3 (TLR-3) agonist molecules to activate the innate immune cells, such as dendritic cells, macrophages and NK cells. PIKA adjuvant is formulated as a component of PIKA-adjuvant based hepatitis vaccine.

About Yisheng Biopharma Co., Ltd.
Yisheng Biopharma Co., Ltd. is a biopharmaceutical company headquartered in Beijing, China, focusing on the research, development, manufacturing and sales and marketing of immunological therapeutics in oncology, immunology and infectious diseases, with approximately 1000 employees in China, the USA and Singapore. 
www.yishengbio.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/yisheng-biopharma-announces-completion-of-phase-i-clinical-study-of-a-novel-hepatitis-b-vaccine-with-pika-adjuvant-300366327.html


'/>"/>
SOURCE Yisheng Biopharma Co., Ltd.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Yisheng Biopharma and the United States Army Medical Research Institute of Infectious Diseases Announce Collaboration on New Vaccine Against Ebola Virus
2. Samenwerking tussen Yisheng Biopharma en het United States Army Medical Research Institute of Infectious Diseases aan een nieuw vaccin tegen ebolavirus
3. Yisheng Biopharma und das United States Army Medical Research Institute of Infectious Diseases verkünden Zusammenarbeit an neuem Impfstoff gegen das Ebolavirus
4. Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
5. Yisheng Biopharma maakt positief resultaat bekend van klinische onderzoeksfase I van nieuw rabiës vaccin met PIKA-adjuvans
6. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
7. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
8. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
9. New Prefillable Syringe System Offers Advanced Glass Technology for Biopharmaceutical Injectable Drug Delivery
10. TransCelerate BioPharma Inc. Reveals Collaborative Methodology for Risk-Based Monitoring of Clinical Trials
11. Array BioPharma Announces Proposed Public Offering of Convertible Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):